收费全文 | 21242篇 |
免费 | 1337篇 |
国内免费 | 146篇 |
耳鼻咽喉 | 286篇 |
儿科学 | 668篇 |
妇产科学 | 723篇 |
基础医学 | 2236篇 |
口腔科学 | 618篇 |
临床医学 | 1817篇 |
内科学 | 4717篇 |
皮肤病学 | 363篇 |
神经病学 | 973篇 |
特种医学 | 706篇 |
外国民族医学 | 1篇 |
外科学 | 3636篇 |
综合类 | 634篇 |
现状与发展 | 1篇 |
一般理论 | 19篇 |
预防医学 | 1408篇 |
眼科学 | 603篇 |
药学 | 1850篇 |
中国医学 | 178篇 |
肿瘤学 | 1288篇 |
2023年 | 220篇 |
2022年 | 631篇 |
2021年 | 982篇 |
2020年 | 597篇 |
2019年 | 766篇 |
2018年 | 895篇 |
2017年 | 585篇 |
2016年 | 669篇 |
2015年 | 655篇 |
2014年 | 926篇 |
2013年 | 1172篇 |
2012年 | 1644篇 |
2011年 | 1612篇 |
2010年 | 928篇 |
2009年 | 728篇 |
2008年 | 1165篇 |
2007年 | 1228篇 |
2006年 | 1067篇 |
2005年 | 975篇 |
2004年 | 867篇 |
2003年 | 717篇 |
2002年 | 674篇 |
2001年 | 275篇 |
2000年 | 243篇 |
1999年 | 239篇 |
1998年 | 130篇 |
1997年 | 93篇 |
1996年 | 89篇 |
1995年 | 81篇 |
1994年 | 88篇 |
1993年 | 58篇 |
1992年 | 155篇 |
1991年 | 116篇 |
1990年 | 143篇 |
1989年 | 120篇 |
1988年 | 107篇 |
1987年 | 107篇 |
1986年 | 86篇 |
1985年 | 87篇 |
1984年 | 69篇 |
1983年 | 60篇 |
1982年 | 43篇 |
1980年 | 43篇 |
1979年 | 62篇 |
1977年 | 53篇 |
1976年 | 41篇 |
1974年 | 49篇 |
1973年 | 49篇 |
1972年 | 34篇 |
1970年 | 34篇 |
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献